Manages pain severe enough to require an opioid analgesic. ANDA 70916, held by Hospira. Nalbuphine Hydrochloride.
As of Nov 22, 2026, ANDA 70916 (Nalbuphine Hydrochloride), held by Hospira, was first approved by FDA on Feb 3, 1989, with 15 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Nalbuphine Hydrochloride Injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Nalbuphine Hydrochloride Injection can also be used as a supplement to balanced anesthesia, for preoperative and postoperative analgesia, and for obstetrical analgesia during labor and delivery.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 3, 1989 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Nalbuphine Hydrochloride20MG/ML (20MG/ML) · solution;intramuscular, intravenous, subcutaneous | Nalbuphine Hydrochloride | Rx |
| Dec 22, 2025 | Supplement 28Labeling · Standard review | Approved | None posted |
| Aug 27, 2024 | Supplement 25Labeling · Standard review | Approved | None posted |
| Dec 15, 2023 | Supplement 23Labeling · Standard review | Approved | None posted |
| Dec 1, 2023 | Supplement 20Labeling · Standard review | Approved | None posted |
| Oct 16, 2019 | Supplement 19Labeling · Standard review | Approved | None posted |
| Dec 16, 2016 | Supplement 18Labeling · Standard review | Approved | None posted |
| Dec 16, 2016 | Supplement 17Labeling · Standard review | Approved | None posted |
| Nov 30, 2007 | Supplement 12Labeling | Approved | None posted |
| Jul 12, 1999 | Supplement 10Manufacturing | Approved | None posted |
| Jan 24, 1997 | Supplement 9Manufacturing | Approved | None posted |
| Jan 24, 1997 | Supplement 8Manufacturing | Approved | None posted |
| Oct 3, 1996 | Supplement 7Manufacturing | Approved | None posted |
| Apr 26, 1996 | Supplement 5Labeling | Approved | None posted |
| Feb 28, 1991 | Supplement 3Labeling | Approved | None posted |
| Jul 25, 1990 | Supplement 2Labeling | Approved | None posted |
| Feb 3, 1989 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters